Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating. Mesa Laboratories’ rating score has improved by 50% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokers have set a 12 month consensus price objective of $190.00 for the company and are forecasting that the company will post $0.85 EPS for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 155 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 price target on the stock in a research report on Tuesday, June 13th.

ILLEGAL ACTIVITY NOTICE: “Mesa Laboratories, Inc. (NASDAQ:MLAB) Given Consensus Rating of “Strong Buy” by Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/20/mesa-laboratories-inc-nasdaqmlab-given-consensus-rating-of-strong-buy-by-brokerages.html.

In other news, Director David M. Kelly sold 1,000 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $142.00, for a total transaction of $142,000.00. Following the sale, the director now directly owns 4,750 shares of the company’s stock, valued at $674,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert V. Dwyer sold 11,150 shares of the business’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $139.46, for a total transaction of $1,554,979.00. Following the sale, the director now directly owns 80,671 shares in the company, valued at $11,250,377.66. The disclosure for this sale can be found here. Insiders have sold 16,150 shares of company stock worth $2,292,899 over the last three months. Corporate insiders own 17.00% of the company’s stock.

A hedge fund recently raised its stake in Mesa Laboratories stock. Eqis Capital Management Inc. increased its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 5.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,188 shares of the medical instruments supplier’s stock after buying an additional 273 shares during the period. Eqis Capital Management Inc. owned about 0.14% of Mesa Laboratories worth $744,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 65.15% of the company’s stock.

Shares of Mesa Laboratories (NASDAQ:MLAB) traded down 0.52% during mid-day trading on Thursday, reaching $153.40. The company’s stock had a trading volume of 1,476 shares. The firm’s 50 day moving average is $146.91 and its 200 day moving average is $133.65. The firm has a market cap of $573.26 million, a PE ratio of 52.71 and a beta of 0.46. Mesa Laboratories has a one year low of $102.14 and a one year high of $169.80.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Wednesday, June 7th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.24. The business had revenue of $24.30 million for the quarter, compared to the consensus estimate of $27.10 million. Mesa Laboratories had a return on equity of 17.67% and a net margin of 11.94%. On average, equities analysts anticipate that Mesa Laboratories will post $3.06 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Tuesday, August 29th. Mesa Laboratories’s dividend payout ratio (DPR) is presently 21.99%.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.